Lipid nanoparticles have redefined what’s possible in drug delivery, from recent acclaim in COVID-19 vaccines to a storied history of novel drug delivery mechanisms. However, it may come with a price: immune reactions that can compromise the safety and efficacy of PEGylated lipid nanoparticles. With a clinical pipeline full of exciting new RNA therapeutics, how can we overcome this? Learn more about the emerging trends, opportunities, and challenges in our latest peer-reviewed publication in Bioconjugate Chemistry.
Read the Journal Publication
